

## 1. General Information

|                               |  |
|-------------------------------|--|
| <b>Cohort ID</b>              | 5007_18  |
| <b>Title (Study Name)</b>     | HCM Register   |
| <b>Principal investigator</b> | Dr. Nicolas Verheyen, Dr. Klemens Ablasser                             |
| <b>Contact information</b>    | <a href="mailto:pm-biobank@medunigraz.at">pm-biobank@medunigraz.at</a> |
| <b>Funding agency</b>         | Pfizer, Medical University Graz  |

## 2. Description

|  |
|--|
| Blood samples as well as urine samples have been collected at the department of cardiology from patients diagnosed with hypertrophic cardiomyopathy (HCM). |
|--|

## 3. Details

|   |  |               |
|---|--|---------------|
| <b>ICD 10/O codes / Healthy</b>             | I42.2  |               |
| <b>Key words</b>                            | hypertrophic cardiomyopathy, HCM, biomarkers, cardiac amyloidosis  |               |
| <b>Collection / Cohort size</b><br>12/2023  | 16.381 aliquots from 469 patients  |               |
| <b>Informed Consent (IC)</b>                | <input checked="" type="checkbox"/> Broad Biobank IC   |               |
|   | <input checked="" type="checkbox"/> Specific Study IC  |               |
| <b>Status</b>                               | <input checked="" type="checkbox"/> In progress / compl. date: 2024  |               |
|   | <input type="checkbox"/> Completed   |               |
| <b>Inclusion criteria</b>                   | <b>Age distribution</b>  | 18+           |
|   | <b>Sex distribution (f:m)</b>  | ~40:60        |
|   | <b>Others</b>  | confirmed HCM |
| <b>Earliest access</b>                      | As of now  |               |
| <b>Quality-standards</b>                    | <input checked="" type="checkbox"/> ISO 9001:2015 (SOPs)   |               |
| <b>Associated publications / references</b> | <u>Myocardial Deformation Analysis in MYBPC3 and MYH7 Related Sarcomeric Hypertrophic Cardiomyopathy-The Graz Hypertrophic Cardiomyopathy Registry</u><br>Höller V, Seebacher H, Zach D, Schwegel N, Ablasser K, Kolesnik E, Gollmer J, Waltl G, Rainer PP, Verheyen S, Zirlík A, Verheyen N.<br><a href="https://pubmed.ncbi.nlm.nih.gov/34680864/">https://pubmed.ncbi.nlm.nih.gov/34680864/</a> |               |

## 4. Material available (aliquot size) and storage conditions

|                 |  |   |
|-----------------|--|---|
| <b>Material</b> | <input checked="" type="checkbox"/> Serum (580 µl)             | <input checked="" type="checkbox"/> -80°C |
|                 | <input checked="" type="checkbox"/> EDTA plasma (580 µl)       | <input checked="" type="checkbox"/> -80°C |
|                 | <input checked="" type="checkbox"/> EDTA Buffy coat (300 µl)   | <input checked="" type="checkbox"/> -80°C |
|                 | <input checked="" type="checkbox"/> Na-Citrate plasma (580 µl) | <input checked="" type="checkbox"/> -80°C |
|                 | <input checked="" type="checkbox"/> Urine (580 µl)             | <input checked="" type="checkbox"/> -80°C |

|  |  |
|--|--|
| <b>Dokument erstellt</b> (tt/mm/yyyy):<br>09/09/2021 | <b>Letzte inhaltliche Aktualisierung</b> (tt/mm/yyyy):<br>19/03/2024 |
|--|--|